Hit Identification and Lead Optimization
Protein-Ligand Structure-Based Virtual Screening
Our innovative research in computer-aided drug design has evolved into cutting-edge commercial solutions that offer guaranteed results. If our screening campaign yields no results, we will run another campaign against the same target for no additional cost.
With our advanced automated pipelines, we conduct structure-based virtual screening of ultra-large libraries of small molecules, achieving unmatched high hit rates and cost efficiency.
Contact Us
contact@biosieve.com
Meet the Team
Slava Naprienko, PhD
CEO & Co-Founder
I develop new methods in computational drug discovery using advanced mathematics, statistics, and machine learning.
Before starting BioSieve, I was a mathematician working in mathematical physics, statistical mechanics, and representation theory.
Ian Scott Knight
CTO & Co-Founder
I build software to solve problems in biophysical research.
I specialize in the automation and optimization of molecular docking pipelines.
Amber Huang
CDO & Co-Founder
I use data science to train machine learning models in computational drug discovery.
Before starting BioSieve, I designed a price prediction model for items from reselling websites and used this model to built a profitable e-commerce business.